Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2030-11-01
Target enrollment:
Participant gender:
Summary
For resectable non-small cell lung cancer, neoadjuvant immunochemotherapy plus adjuvant
immunotherapy or adjuvant immunochemotherapy is usually used in clinical practice. However,
it is unclear whether therapeutic strategy is superior. This trial aims to compare the
efficacy and safety of these two strategies.